Stanford, Apple Describe Heart Study with over 400,000 Participants

A clinical trial to determine whether a smartwatch app that analyzes pulse-rate data can screen for a heart-rhythm disorder has enrolled more than 400,000 participants. Researchers at Stanford Medicine, in collaboration with Apple, launched the Apple Heart Study last November to determine whether a mobile app that uses the optical sensor on the Apple Watch to analyze pulse rate data can identify atrial fibrillation. The condition, which is characterized by an irregular heartbeat, often remains hidden because many people don't experience symptoms. Atrial fibrillation can increase the risk of stroke and heart failure.

A paper to be published online Nov. 1 in the American Heart Journal describes the design of this unique clinical trial, the largest screening study on atrial fibrillation ever done. Enrollment, which was conducted through an iPhone app, is now closed.

The study has entered the final phase of data collection and will be completed early next year, the researchers said. The Stanford team is led by principal investigators Mintu Turakhia, MD, associate professor of cardiovascular medicine, and Marco Perez, MD, assistant professor of cardiovascular medicine, and by study chair Kenneth Mahaffey, MD, professor of cardiovascular medicine.

"We hope this study will help us better understand how wearable technologies can inform precision health," said Lloyd Minor, MD, dean of the School of Medicine. "These new tools, which have the potential to predict, prevent and manage disease, are finally within our reach."

The Food and Drug Administration announced Sept. 11 that it had cleared two mobile medical apps designed by Apple to work on the Apple Watch. One app uses data from new hardware on the Apple Watch Series 4 to take an electrocardiogram by touching the button on the side of the device. The other app uses data from an optical sensor available on the Apple Watch Series 1 and later to analyze pulse data to identify irregular heart rhythms suggestive of atrial fibrillation and notify the user. The Apple Heart Study involves only this second app.

"The advantage of the app that uses the optical sensor is that it can check for an irregular pulse multiple times throughout the day in the background, without needing the user to actively engage the application," Perez said.

Goals of the study

Each year in the United States, atrial fibrillation results in 130,000 deaths and 750,000 hospitalizations, according to the Centers for Disease Control and Prevention. The CDC estimates that the condition affects between 2.7 million and 6.1 million people. In addition, another 700,000 people may have undiagnosed atrial fibrillation.

Each participant in the study is required to have an Apple Watch (series 1, 2 or 3) and an iPhone. An app on the phone intermittently checks the heart-rate pulse sensor for measurements of an irregular pulse. If sufficient episodes of an irregular pulse are detected, then the participant receives a notification and is asked to schedule a visit with a doctor involved in the study. Participants are then sent electrocardiography patches, which record the electrical rhythm of their hearts for up to a week.

The goals of the study are threefold: to determine how many among those who receive irregular pulse notifications are found to have atrial fibrillation on ECG patch monitoring; to determine how many among those who received an irregular pulse notification go on to get medical attention; and to determine the accuracy of irregular-pulse detection by the watch by comparing it with the simultaneous ECG patch recordings.

"We now have access to high-quality sensors that can measure and detect changes in our bodies in entirely new and insightful ways without even needing to go to the doctor, but we need to rigorously evaluate them," Turakhia said. "There's never really been a study like this done before."

A subset of the study data was used by Apple as part of its regulatory submission for FDA clearance of the smartwatch app that analyzes pulse-rate data. Apple Heart Study investigators were aware of the submission, but have not seen the submission data.

"We are inspired by the overwhelming response to the Apple Heart Study," said Sumbul Desai, MD, vice president of Apple. "Through the combined power of our participants, Apple Watch and Stanford Medicine, it's one of the largest and most novel atrial fibrillation studies to date."

Mintu P Turakhia, Manisha Desai, Haley Hedlin, Amol Rajmane, Nisha Talati, Todd Ferris, Sumbul Desai, Divya Nag, Mithun Patel, Peter Kowey, John S Rumsfeld, Andrea M Russo, Mellanie True Hills, Christopher B Granger, Kenneth W Mahaffey, Marco V Perez.
Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study.
American Heart Journal. doi: 10.1016/j.ahj.2018.09.002.

Most Popular Now

Top 20 Breaking eHealth News of 2018

eHealthNews.eu proudly presents the top 20 most popular breaking eHealth news from 2018. Have a wonderful 2019 New(s) Year filled with health, happiness, and spectacular success!

Artificial Intelligence Advances Threate…

Advances in artificial intelligence have created new threats to the privacy of people's health data, a new University of California, Berkeley, study shows. Led by UC Berkeley engineer Anil Aswani...

Shaping Cloud Selects Highland Marketing…

Public sector cloud transformation specialists Shaping Cloud have chosen Highland Marketing as their marketing and PR partner to help them deliver their growth ambitions in the burgeoning health and care...

Rewired Pitchfest Launched to Showcase B…

Digital health innovators and start-ups are invited to pitch their disruptive ideas and prototypes to NHS digital leaders and leading healthtech investors at the new Digital Health Rewired event next...

Allscripts Joins with Microsoft to Explo…

Today, Allscripts (NASDAQ:MDRX), a global leader in health care information technology, announced a collaboration with Microsoft focused on implementing an innovative, integrated model for clinical research, aiming to enhance clinical...

Merck Welcomes Ten New Startups to its I…

Merck, a leading science and technology company, today announced the ten startups that will be joining the seventh intake of its Accelerator program at the Merck Innovation Center in Darmstadt...

First Smartphone App to Detect Opioid Ov…

At least 115 people die every day in the U.S. after overdosing on opioids, according to the National Institute on Drug Abuse. And in 2016, illegal injectable opioids became the...

Stanford Researchers Create a Wireless, …

A new device developed by Stanford University researchers could make it easier for doctors to monitor the success of blood vessel surgery. The sensor, detailed in a paper published Jan...

AI Approach Outperformed Human Experts i…

A research team led by investigators from the National Institutes of Health and Global Good has developed a computer algorithm that can analyze digital images of a woman's cervix and...

Digital Health Consultancy Invests in Cy…

Digital health consultancy Populo Consulting has secured Cyber Essentials Plus certification, in a move that demonstrates its commitment to operating to the same high standards as its NHS clients. Cyber Essentials...

Boehringer Ingelheim Initiates a Collabo…

Science 37, an industry leader in virtual clinical trials, and Boehringer Ingelheim announced a technology enterprise collaboration agreement that will support Boehringer Ingelheim in running remote clinical trials. Science 37...